IONIS PHARMACEUTICALS, INC. (NASDAQ:IONS) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On June 18, 2018, Ionis Pharmaceuticals, Inc. (the “Company”) announced that Damien McDevitt, Ph.D., age 51, has joined the Company as chief business officer. In this position, Dr. McDevitt will provide strategic guidance and lead Ionis’ corporate development activities, including corporate communications, business development, patient advocacy, competitive intelligence and alliance management, and will serve as a member of Ionis’ executive leadership team.
A copy of the press release announcing Dr. McDevitt’s position is included with this report as exhibit 99.1 and incorporated herein by reference.
Item 9.01.Financial Statements and Exhibits.
(d) Exhibits.
| 99.1 |
Press Release dated June 18, 2018. |
IONIS PHARMACEUTICALS INC ExhibitEX-99.1 2 ex99_1.htm EXHIBIT 99.1 Exhibit 99.1 Ionis Pharmaceuticals Appoints Damien McDevitt as Chief Business Officer Carlsbad,…To view the full exhibit click here
About IONIS PHARMACEUTICALS, INC. (NASDAQ:IONS)
Ionis Pharmaceuticals, Inc., formerly Isis Pharmaceuticals, Inc., is engaged in discovering and developing ribonucleic acid-targeted (RNA-targeted) therapeutics. The Company operates through two segments: Ionis Core and Akcea Therapeutics. The Company’s Ionis Core segment is developing a drug discovery platform. The Company’s Akcea Therapeutics segment consists of the operations of its subsidiary, Akcea Therapeutics, Inc., which develops and commercializes drugs for cardiometabolic disorders. The Company is developing transformational drugs, which include nusinersen, IONIS-TTR and volanesorsen that are designed to treat patients with orphan diseases. In addition to its Phase III programs, the Company has a pipeline of drugs in Phase II development, which includes IONIS-FXI and IONIS-APO(a)-L. Its Phase II pipeline includes drugs to treat patients with severe and rare diseases, viral infections, ocular diseases, metabolic disorders and cardiovascular diseases.
